EGFR and lung adenocarcinoma: We demonstrated that in patients with stage IV lung adenocarcinoma harboring susceptible EGFR mutations, an initial dose of 30 mg daily of afatinib may not be inferior to 40 mg daily with regards to response rate, PFS, and OS.